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A cDNA encoding the mature human cysteine proteinase inhibitor cystatin C was fused to the coding sequence for the 
Escherichia coli outer membrane protein A signal peptide, and the recombinant gene was expressed in E. coli under the 
control of the I Ps promoter, an optimized Shine-Dalgamo sequence and the rZ ~I857 repressor. When induced at 42°C 
such cells expressed large amounts of recombinant cystatin C. The recombinant protein was isolated in high yield and 
characterized. All physicochemical properties investigated, including the positions of disulfide bonds, indicated that the 
E. coli derived cystatin C was identical to cystatin C isolated from human biological fluids, except that the proline residue 
in position three was not hydroxylated. The recombinant protein displayed full biological activity against papain, 
cathepsin B and dipeptidyl peptidase I. 
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1. INTRODUCTION 
Cystatin C belongs to a recently defined super- 
family of proteins called the cystatin superfamily 
comprising inhibitors of cysteine proteinases [1,2] 
and is present in all human biological fluids in con- 
centrations implying a physiological importance of 
cystatin C as a controlling inhibitor of extracellular 
cysteine proteinases [3]. Cystatin C is the 
dominating cysteine proteinase inhibitor in 
cerebrospinal fluid and accidental chymopapain 
injection into the cerebrospinal fluid at cysteine 
proteinase treatment of sciatica results in massive 
cerebral hemorrhage when the inhibiting capacity 
of cystatin C is exceeded [4]. In hereditary cystatin 
C amyloid angiopathy’young adults are affected by 
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massive, often fatal, cerebral hemorrhage. This 
disease is associated with an abnormally low con- 
centration of cystatin C in cerebrospinal fluid [5] 
and with deposition of a cystatin C variant as 
amyloid [6,7]. Access to large amounts of native 
cystatin C is required for further elucidation of the 
biological activities of the protein as well as for 
preventive and therapeutic trials at cerebral hemor- 
rhages associated with low cerebrospinal fluid 
levels of cystatin C. The present work was under- 
taken to establish an E. coli expression system 
allowing not only the production of large amounts 
of native cystatin C but also the future production 
of cystatin C variants enabling an assessment of 
the biological and clinical importance of various 
amino acid substitutions in the molecule. 
2. MATERIALS AND METHODS 
2.1. Materials 
Restriction enzymes and other DNA modifying enzymes were 
from Amersham. Carboxypeptidase Y was purchased from 
Boehringer. Cathepsin B (EC 3.4.22.1) and dipeptidyl peptidase 
I (type X) (EC 3.4.14.1), both from bovine spleen, were ob- 
tained from Sigma. Papain (EC 3.4.22.2) isolated from crude 
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Papaya latex by affinity chromatography on Gly-Gly-Tyr(Bzl)- 
Arg-Sepharose [8], activatable to 90%, was a kind gift from Drs 
I. Bjiirk and P. Lindahl, Uppsala, Sweden. Enzyme substrates 
were from Bachem. Q Sepharose and Biogel P-60 were from 
Pharmacia and BioRad, respectively. 
2.2. Construction of expression vector and conditions for 
expression 
Plasmid pUClWC6a [9] which contains a full-length cystatin 
C cDNA inserted at the EcoRI site in the polylinker of pUC18, 
was cut with NcoI/HindIII. The N-terminal part of the gene 
was substituted with a synthetic linker reconstituting the coding 
sequence for mature cystatin C enabling in frame fusion to a 
DNA fragment encoding the signal peptide from the E. coli 
outer membrane protein A (OmpA). From the resulting plasmid 
an approx. 720 bp CluI/EcoRI DNA fragment containing the 
OmpA signal peptide fused in frame to the cystatin C gene was 
isolated. The fragment was introduced into plasmid pHD234 
which contains the h c1 857 temperature sensitive repressor 
gene, the h PR promoter, an optimized Shine-Delgarno se- 
quence [lo] and the polylinker from pUCl8 resulting in the ex- 
pression plasmid pHD3 13. 
The plasmid was introduced into E. coli MC1061 and 
propagated in 1 1 TB medium containing 100 yg/ml ampicillin. 
The expression of cystatin C was induced by increasing the 
temperature from 30°C to 42°C for 3 h at an initial A.sc+ of ap- 
prox. 5. The cells were harvested by centrifugation. 
2.3. Isolation and physicochemical characterization of 
cystatin C 
Cystatin C from bacterial suspensions or human urine was 
isolated by anion-exchange and gel chromatographies using col- 
umns of Q Sepharose and Biogel P-60 after concentration of the 
starting material by ultrafiltration, under the conditions 
described in [3]. Individual references and equipments used for 
agarose and SDS-polyacrylamide gel electrophoreses, amino 
acid analysis and automated N-terminal amino acid sequence 
analysis are given in [3]. Direct sequencing from crude bacterial 
extracts was accomplished by blotting proteins separated by 
agarose gel electrophoresis onto a PVDF membrane, staining 
by Coomassie blue and putting the membrane segment carrying 
the relevant protein directly into the gas-phase sequenator [l 11. 
Analysis of disulfide-linked peptides by diagonal high-voltage 
electrophoresis was performed as described earlier [12]. Con- 
centrations of isolated cystatin C were determined spec- 
trophotometrically (,42s0,1~~ = 9.1 [13]) and by amino acid 
analysis and of cystatin C in crude extracts by single radial im- 
munodiffusion using a polyclonal antiserum and a standard 
previously described [3]. Total protein was measured by quan- 
titative amino acid analysis. 
2.4. Analysis of biological activity 
Papain and cathepsin B activity was assayed at 37’C in 0.1 M 
phosphate buffer, pH 6.5, containing 1 mM DTT and 1 mM 
EDTA. The concentration of active cysteine proteinase in pa- 
pain and cathepsin B solutions was determined by titration with 
compound E-64 (141. Dipeptidyl peptidase activity was also 
assayed at 37°C and pH 6.5, but in 0.1 M phosphate buffer 
containing 50 mM NaCl, 2 mM DTT and 1 mM EDTA. Cys- 
teine proteinase inhibitory activity in crude E. coli extracts was 
determined by incubation with papain and assessment of 
residual activity using Z-Phe-Arg-NHMec. The activities in 
solutions of isolated expression product or human cystatin C 
were compared by papain titration using the substrate Bz-Arg- 
pNA and relating the results to total cystatin C content as 
measured by amino acid analysis. Apparent equilibrium and 
dissociation rate constants for interactions between the isolated 
expression product and papain, cathepsin B and dipeptidyl pep- 
tidase I were calculated from continuous rate assays [15] using 
10 pM Z-Phe-Arg-NHMec, Z-Phe-Arg-NHMec, and Gly-Arg- 
NHMec, respectively. 
3. RESULTS 
In order to produce mature cystatin C in the 
periplasm of E. coli, the 5 ‘-end of a cystatin C 
cDNA insert, including the part coding for the 
signal peptide as well as the 13 N-terminal amino 
acids of mature cystatin C, was excised and re- 
placed by a synthetic linker reconstituting the 
coding sequence for mature cystatin C and en- 
abling in frame fusion to a DNA encoding the E. 
co/i OmpA signal peptide (fig.1). The modified 
cDNA insert was ligated into an expression vector 
containing the X PR promoter, an optimized Shine- 
Dalgarno sequence and the A c1 857 repressor 
(fig.2). After expression had been induced in E. 
coli transformed with this plasmid, cell extracts 
obtained by osmotic shock contained large 
amounts of cystatin C immunoreactive material, in 
contrast to cell extracts from non-induced bacteria 
or bacteria not harbouring the expression plasmid. 
The extracts also displayed papain inhibitory ac- 
tivity. After optimizing the conditions for growth 
and expression, expression levels corresponding to 
10% of the total protein content was obtained. 
Sequencing of the expression product gave the N- 
terminal sequence SSPGKPPRLVGGPMDASVE- 
EEGV--ALDFAVGEYNKASNDMY-S, showing 
that the OmpA signal peptide-cystatin C fusion 
protein was correctly processed at the Ala-‘-Ser’ 
bond by the E. coli signal peptidase (fig.1). 
The expression product was purified to 
homogeneity from concentrated cell extracts by a 
simple procedure comprising chromatography on 
Q Sepharose at pH 9.5 and gel chromatography on 
Biogel P-60 of the non-adsorbed fraction. No 
significant proteolytic degradation was obtained at 
the high pH used in the initial phase of the isola- 
tion, thereby obviating the need for addition of 
protease inhibitors. The yield of the isolation pro- 
cedure was 50-55’70. 
The physicochemical properties of the isolated 
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MetLysLysThrAlaIleAlaIleAlaVal 
5'- ATCGATGAAAAAAA CTGCTATCGCTATCGCTGTT 
3'- TAGCTACTTTTTTTGACGATAGCGATAGCGACAA 
Cla1 
-11 -1 1 
1 AlaLeuAlaGlyPheAlaThrValAlaGlnAla SerSer 
GCTCTGGCTGGTTTCGCTACTGTTGCTCAGGCG TCTTCT 
CGAGACCGACCAAAGCGATGACAACGAGTCCGC AGAGAG 
ProGlyLysProProArgLeuValGlyGlyProMet... 
CCGGGTAAACCGCCGCGTCTGGTTGGTGGTCCCATGG - 
GGCCCATTTGGCGGCGCAGACCAACCACCAGGGTACC - ’ 
NcoI 
Fig.1. DNA and corresponding amino acid sequences of the 
modified region of the cystatin C cDNA. The linker sequence 
reconstituting the sequence encoding mature cystatin C was 
assembled from two oligonucleotides, and ligated to NcoI 
digested cDNA. This construct was then fused in frame to a 
synthetic sequence encoding the OmpA signal peptide. The site 
of cleavage by the E. coli signal peptidase is shown by an arrow. 
expression product was compared to those of 
cystatin C isolated from human urine by the same 
procedure. Agarose and SDS-polyacrylamide gel 
electrophoreses howed that the proteins had the 
same charge and molecular mass (fig.3). Amino 
acid analyses gave identical results for the two pro- 
teins, within the limits of experimental errors (not 
shown). These data in conjunction with the 42 
identified N-terminal amino acid residues of the 
expression product strongly indicated that the 
primary structure of the E. coli produced cystatin 
C was essentially identical to that of cystatin C of 
pepride 
Amp’ 
cystatin C 
Fig.2. The expression vector pHD313 carrying DNA sequences 
for an OmpA signal peptide-cystatin C fusion preprotein. Only 
relevant restriction sites are shown. 
- 
M,x 10 -3 
\ 67 
- 20.1 
123 
‘Fig.3. Electrophoretic analyses of (lane 1) extract of pHD313 
transformed E. coli MC1061 after induction of expression; (2) 
isolated E. coli produced cystatin C; and (3) cystatin C isolated 
from human urine. (A) Agarose gel electrophoresis at pH 8.6. 
The anode and point of sample application is shown by a plus 
sign and an arrow, respectively. (B) SDS-polyacrylamide 
electrophoresis at reducing conditions. (Far right) The positions 
of molecular mass markers. 
human origin. In addition, amino acid analysis of 
the disulfide bonded peptides showed that the E. 
coii produced cystatin C had two disulfide bridges 
spanning the same cysteine residues as the disulfide 
bridges in human cystatin C, and also gave strong 
evidence for a correct C-terminal sequence [121. 
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Table 1 
Comparison between inhibitory properties of E. coli produced 
cystatin C and cystatin C from human urine 
Kiopr) (nM) 
Papain 
Cathepsin B 
DPP I 
E. coli 
produced 
< 0.005 
0.50 
3.1 
Human 
origin 
< 0.005 
0.21 
6.3 
The molar concentration of active cysteine pro- 
teinase inhibitor in solutions of isolated expression 
product and cystatin C from human urine was 
measured by titration of a papain solution of 
known active enzyme concentration (see section 2) 
and compared to the total cystatin C concentration 
as measured by quantitative amino acid analysis. 
As estimated this way, the expression product 
displayed a molar inhibitory activity of 83%, 
whereas that of cystatin C from human urine only 
displayed an inhibitory activity of 55%. The ap- 
parent equilibrium constants, Kr(app), for interac- 
tions between E. coli produced cystatin C and 
papain, cathepsin B and dipeptidyl peptidase I at 
37’C and pH 6.5 were determined and compared 
to the corresponding values for cystatin C isolated 
from human urine (table 1). Also, the rate constant 
for dissociation of the enzyme-inhibitor complex, 
kml, was calculated for the two cystatin C prepara- 
tions interacting with cathepsin B. The k_~~,,,~ 
value for E. coli produced cystatin C was 0.9 x 
low3 s-l, in close agreement with the value of 0.8 
x low3 s-i obtained for cystatin C of human 
origin. 
4. DISCUSSION 
The presently described E. coli expression 
system allows production of cystatin C in- 
distinguishable from cystatin C of human origin 
with respect to all tested physicochemical proper- 
ties, the only exception being that the proline in 
position three of cystatin C isolated from human 
biological fluids typically is hydroxylated to 50% 
[ 161 whereas the E. coli produced material is not. 
The biological activity of E. coli produced cystatin 
C was very similar to that of the human material, 
since it displayed tight binding to the model en- 
zyme for cysteine proteinases, papain, and to the 
well-characterized mammalian lysosomal cysteine 
proteinase, cathepsin B; it also inhibited the 
lysosomal mammalian exopeptidase dipeptidyl 
peptidase I. The Ki and k-1 values calculated for 
those interactions were within experimental errors 
identical to the corresponding values for cystatin C 
from human urine reported here and earlier [3,17]. 
The highest molar inhibitory concentration to 
date measured in preparations of cystatin C of 
human origin (measured as inhibition of papain 
activity against low M, substrates), amounts to 
50-60% of the total protein concentration [3]. The 
reason for the occurrence of a large proportion of 
apparently biologically inactive cystatin C in such 
preparations is unknown and it is therefore of con- 
siderable interest hat the preparations of recombi- 
nant cystatin C described in this work have 
biological activities amounting to more than 80% 
of their protein concentrations. 
The E. co/i expression system described in this 
work for the production of large amounts of 
recombinant cystatin C, apparently identical to 
human cystatin C, will probably allow preventive 
and therapeutic trials aiming at increasing the cys- 
teine proteinase inhibitory capacity of biological 
fluids in which low levels of cystatins are 
associated with pathophysiological processes. The 
system might also be used for site-directed 
mutagenesis to produce variants of cystatin C for 
studies on structure-function relationships, with 
respect to inhibitory properties and, more 
specifically, to investigate if the replacement of a 
leucine residue at position 68 of cystatin C with a 
glutamine residue could be the cause of amyloid 
formation in hereditary cystatin C amyloid 
angiopathy [7]. 
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